Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia

Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary.

1. Golubev V.L., Levin Ya.I., Veyn A.M. Parkinson’s disease and parkinson’s syndrome. Moscow: MEDpress; 1999. (In Russ.)

2. Levin O.S., Fedorova N.V. Parkinson’s disease. Moscow; 2016. (In Russ.)

3. Antonini A., Tolosa E., Mizuno Y., Yamamoto M., Poewe W.H. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol. 2009;8(10):929-937. doi: 10.1016/S1474-4422(09)70225-X.

4. Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl. 2006;(70):419-426. doi: 10.1007/978-3-211-45295-0_63.

5. Suchowersky O., Reich S., Perlmutter J., Zesiewicz T., Gronseth G., Weiner WJ. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):968-975. doi: 10.1212/01.wnl.0000215437.80053.d0.

6. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA. 2000;284(15):1931-1938. doi: 10.1001/jama.284.15.1931.

7. Nutt J.G., Carter J.H., Woodward W.R. Long-duration response to levodopa. Neurology. 1995;45(8):1613-1616. doi: 10.1212/WNL.45.8.1613.

8. Nutt J.G., Carter J.H., Van Houten L., Woodward W.R. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol. 1997;42(3):349-355. doi: 10.1002/ana.410420311.

9. Yakhno N.N., Nodel M.R., Fedorova N.V., Artemiev D.V., Levin O.S., Preobrazhenskaya I.S. et al. Efficacy and tolerance of pramipexol (Mirapex) in long-term therapy of patients with Parkinson’s disease. Nevrologicheskiy zhurnal = The Neurological Journal. 2004;9(3):25-30. (In Russ.) Available at: https://elibrary.ru/item.asp?id=17248150.

10. Grosset K., Needleman F., Macphee G., Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: A clinical series and five-drug dose conversion table. MovDisord. 2004;19(11):1370-1374. doi: 10.1002/mds.20210.

11. Grosset K.A., Reid J.L., Grosset D.G. Medicine-taking behavior: Implications of suboptimal compliance in Parkinson’s disease. Mov Disord. 2005;20(11):1397-1404. doi: 10.1002/mds.20525.

12. Hauser R.A., Rascol O., Korczyn A.D., Stoessl AJ., Watts R.L., Poewe W. et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22(16):2409-2417. doi: 10.1002/mds.21743.

13. Rascol O., Brooks DJ., Korczyn A.D., De Deyn P., Clarke C.E., Lang A.E., Abdalla M. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006;21(11):1844-1850. doi: 10.1002/mds.20988.

14. Levin O.S. Treatment of early Parkinson’s disease. Vmire lekarstv = In the World of Drugs. 2001;(1):41-47. (In Russ.)

15. Titova N., Levin O., Katunina E., Chaudhuri K.R. “Levodopa Phobia”: a review of a not uncommon and consequential phenomenon. NPJ Parkinson’s Dis. 2018;4:31. doi: 10.1038/s41531-018-0067-z.

16. Kurlan R. “Levodopa phobia”: a new iatrogenic cause of disability in Parkinson disease. Neurology. 2005;64(5):923-924. doi: 10.1212/01.WNL.0000152880.77812.5B.

17. Rota S., Boura I., Batzu L., Titova N., Jenner P., Falup-Pecurariu C., Chaudhuri K.R. “Dopamine agonist Phobia” in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine. Expert Rev Neurother. 2020;20(9):953-965. doi: 10.1080/14737175.2020.1806059.

18. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V. et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-595. doi: 10.1001/archneu-rol.2010.65.

19. Weintraub D., Nirenberg MJ. Impulse control and related disorders in Parkinson’s disease. Neurodegener Dis. 2013;11(2):63-71. doi: 10.1159/000341996.

20. Antonini A. Continuous dopaminergic stimulation - from theory to clinical practice. Parkinsonism Relat Disord. 2007;13(Suppl.):S24-S28. doi: 10.1016/j.parkreldis.2007.06.002.

21. Nirenberg M.J. Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care. Drugs Aging. 2013;30(8):587-592. doi: 10.1007/s40266-013-0090-z.

22. Rabinak C.A., Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58-63. doi: 10.1001/archneu-rol.2009.294.

23. Levin O.S., Fedorova N.V., Smolentseva I.G. Dopamine receptor agonists in the treatment of Parkinson’s disease. RMZh = RMJ. 2000;(15):643-646. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Agonisty_dofaminovyh_receptorov_v_lechenii_bolezni_Parkinsona/

24. Chaudhuri K.R., Martinez-Martin P., Rolfe KA., Cooper J., Rockett C.B., Giorgi L., Ondo W.G. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol. 2012;19(1):105-113. doi: 10.1111/j.1468-1331.2011.03442.x.

25. Watts R.L., Lyons K.E., Pahwa R., Sethi K., Stern M., Hauser R.A. et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord. 2010;25(7):858-866. doi: 10.1002/mds.22890.

26. Whone A.L., Watts R.L., Stoessl AJ., Davis M., Reske S., Nahmias C. et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54(1):93-101. doi: 10.1002/ana.10609.

27. Levin O.S., Smolentseva I.G., Tserensodnom В., Fedorova N.V., Dokadina L.V Dopaminergic therapy effects on neuropsychological functions in patients with Parkinson’s disease. Nevrologicheskiy zhurnal = The Neurological Journal. 2004;9(3):31-37. (In Russ.) Available at: https://elibrary.ru/item.asp?id=17248151.

28. Patient management protocol. Parkinson’s disease. Problemy standartizatsii vzdravookhranenii = Health care Standardization Problems. 2005;(3):74-166. (In Russ.)

29. Leopold N.A., Polansky M., Hurka M.R. Drug adherence in Parkinson’s disease. Mov Disord. 2004;19(5):513-517. doi: 10.1002/mds.20041.

30. Brooks DJ., Abbott RJ., Lees AJ., Martignoni E., Philcox D.V., Rascol O. et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson’s disease. Clin Neuropharmacol. 1998;21(2):101-107. Available at: https://pubmed.ncbi.nlm.nih.gov/9579296/

31. Claxton AJ., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310. doi: 10.1016/S0149-2918(01)80109-0.

32. Poceta J.S., Parsons L., Engelland S., Kripke D.F. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson’s disease. Sleep Med. 2009;10(1):129-133. doi: 10.1016/j.sleep.2007.11.002.

33. Stocchi F., Giorgi L., Hunter B., Schapira A.H.V. PREPARED: Comparison of Prolonged and Immediate Release Ropinirole in Advanced Parkinson’s Disease. Mov Disord. 2011;26(7):1259-1265. doi: 10.1002/mds.23498.

34. Rascol O., Brooks DJ., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484-1491. doi:10.1056/NEJM200005183422004.

35. Schapira A.H.V., Olanow C.W. Drug selection and timing of initiation of treatment in early Parkinson’s disease. Ann Neurol. 2008;64(S2):S47-S55. doi: 10.1002/ana.21460.

36. Levin O.S., Smolenceva I.G., Cerensodnom B. Efficacy of pramipexole in Parkinson’s disease (based on the results of a 12-month open-label study) Farmateka = Farmateca. 2007;(s3-07). (In Russ.) Available at: https://phar-mateca.ru/ru/archive/article/7024.

37. Dhir A., Kulkarni S.K. Involvement of dopamine (DA)/serotonin (5-HT)/ sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist. Brain Res Bull. 2007;74(1-3):58-65. doi: 10.1016/j.brainres-bull.2007.05.004.

38. Pahwa R., Stacy M.A., Factor S.A., Lyons K.E., Stocchi F., Hersh B.P et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108-1115. doi: 10.1212/01.wnl.0000258660.74391.c1.

39. Rektorova I., Balaz M., Svatova J., Zarubova K., Honig I., Dostal V. et al. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol. 2008;31(5):261-266. doi: 10.1097/WNF.0b013e31815d25ce.

40. Stowe R., Ives N., Clarke C.E., Deane K., van Hilten, Wheatley K. et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson' s disease patients with motor complications. Cochrane Database Syst Rev. 2010;(7):CD007166. doi: 10.1002/14651858.CD007166.pub2.

41. Thobois S. Proposed dose equivalence for rapid switch between dopamine agonists in Parkinson disease: a review of the literature. Clin Ther. 2006;28(1):1-12. doi: 10.1016/j.clinthera.2005.12.003.

42. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson’s Disease. Mov Disord. 2010:25(15):2649-2653. doi: 10.1002/mds.23429.

43. Stocchi F., Hersh B.P., Scott B.L., Nausieda P.A., Giorgi L. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: A randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008;24(10):2883-2895. doi: 10.1185/03007990802387130.